ONTARGET: Similar protection of telmisartan and ramipril, and lack of benefit of combined therapy in patients at high risk for vascular events;Étude clinique du mois. ONTARGET: Protection comparable du telmisartan et du ramipril et absence de bénéfice de la combinaison chez des patients à haut risque vasculaire

Revue Medicale de Liege

Volumn 63, Issue 4, 2008, Pages 213-219

  Scheen, A J ^a,b   Krzesinski, J M ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

ACE inhibitor; Angiotensin receptor blocker; Cardiovascular disease; Dual blockade; Ramipril; Renin angiotensin system; Telmisartan

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIHYDROPYRIDINE; DILTIAZEM; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NITRATE; ORAL ANTIDIABETIC AGENT; RAMIPRIL; TELMISARTAN; TICLOPIDINE; VERAPAMIL; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; ANGIONEUROTIC EDEMA; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL OBSERVATION; COMBINATION CHEMOTHERAPY; COUGHING; DIABETES MELLITUS; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPOTENSION; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; REVIEW; STROKE; SYNCOPE; TREATMENT OUTCOME; VASCULAR DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DRUG THERAPY, COMBINATION; HUMANS; RAMIPRIL; RISK FACTORS; TREATMENT OUTCOME; VASCULAR DISEASES;

EID: 44449101233     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. - Renin-angiotensin system and cardiovascular risk. Lancet, 2007, 369, 1208-1219.
2. Schleich F, Krzesinski JM, Piérard L, Scheen AJ. - Comment je traite... en optimisant le blocage du système rénine-angiotensine- aldostérone. Rev Med Liège, 2008, 63, 174-181.
3. Yusuf S, Sleight P, Dagenais G, et al, for the Heart Outcomes Prevention Evaluation (Hope Study Group). - Effects of the angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New Engl J Med, 2000, 342, 145-153.
4. Krzesinski JM, Montrieux Ch, Scheen AJ. - Inhibiteurs de l'enzyme de conversion de l'angiotensine ou antagonistes des récepteurs de l'angiotensine 2 en pathologie cardio-vasculaire et néphrologique : que nous dit l'Evidence Based Medicine ? Rev Med Liège, 2006, 61, 414-422.
5. The ONTARGET Investigators. - Telmisartan, ramipril, or both in patients at high risk for vascular events. New Engl J Med, 2008, 358, 1547-1559.
6. Kulbertus H. - Telmisartan (Micardis®). Rev Med Liège, 2000, 55, 57-60.
7. Battershill AJ, Scott LJ. - Telmisartan : a review of its use in the management of hypertension. Drugs, 2006, 66, 51-83.
8. Diener HC. - The PRoFESS trial : future impact on secondary stroke prevention. Expert Rev Neurother, 2007, 7, 1085-1091.
9. Barnett AH, Bain SC, Bouter P, et al, for the Diabetics Exposed to Telmisartan and Enalapril (Detail) Study group. - Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. New Engl J Med, 2004, 351, 1952-1961.
10. Friedrich MG, Dahlöf B, Sechtem U, et al, the Telmars investigators. - Reduction (Telmar) As assessed by magnetic resonance imaging in patients with mild to moderate hypertension - a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design. J Renin Angiotensi Aldosterone Syst, 2003, 4, 234-243.
11. Teo K, Yusuf S, Sleight P, et al, for the Ontarget/Transcend Investigators. - Rationale, design and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients : the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan RAndomized Assessment Study in ACE iNtolerant Subjects with cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J, 2004, 148, 52-61.
12. Sleight P. - The ONTARGET/TRANSCEND trial programme : baseline data. Acta Diabetol, 2005, 42, S50-S56.
13. Fitchett D. - Clinical trial update : focus on the ONTARGET study. Vasc Health Risk Manag, 2007, 3, 901-908.
14. Graham I, Atar D, Borch-Johnsen K, et al. - European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Atherosclerosis, 2007, 194, 1-45
15. and Eur Heart J, 2007, 28, 2375,2414.
16. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. - Effect of a multifactorial intervention on mortality in type 2 diabetes. New Engl J Med, 2008, 358, 580-591.
17. Scheen AJ. - Comment j'explore ... les critères de jugement dans les essais cliniques : réflexion à propos d'études récentes de prévention cardio-vasculaire. Rev Med Liège, 2006, 61, 260-266
18. McMurray JJV. - ACE inhibitors in cardiovascular disease - Unbeatable ? New Engl J Med, 2008, 358, 1615-1616.
19. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. - Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New Engl J Med, 2003, 349, 1893-1906.
20. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. - A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med, 2001, 345, 1667-1675.
21. McMurray JJ, Ostergren J, Swedberg K, et al. - Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors : the CHARM-Added trial. Lancet, 2003, 362, 767-771.
22. Nakao N, Yoshimura A, Morita H, et al. - Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inihibitor in non-diabetic renal disease (COOPERATE) : a randomised controlled trial. Lancet, 2003, 361, 117-124.
23. Phillips CO, Kashani A, Ko DK, et al. - Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med, 2007, 167, 1930-1936.